Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Karl Swedberg

Showing results (371-380 of 471) with videos related to

Pageof 48
Sort By:
JACC. Heart Failure|July 5, 2023
Prevalent and Incident Anemia in PARADIGM-HF and the Effect of Sacubitril/ValsartanJames P Curtain, Carly Adamson, Kieran F Docherty, et al.
American Heart Journal|July 6, 2010
Fatal myocardial rupture after acute myocardial infarction complicated by heart failure, left ventricular dysfunction, or both: the VALsartan In Acute myocardial iNfarcTion Trial (VALIANT)Faisal Shamshad, Satish Kenchaiah, Peter V Finn, et al.
Circulation. Heart Failure|October 12, 2017
Prognostic Value of N-Terminal Pro-B-Type Natriuretic Peptide Levels in Heart Failure Patients With and Without Atrial FibrillationSøren Lund Kristensen, Pardeep S Jhund, Ulrik M Mogensen, et al.
European Heart Journal|June 19, 2010
Patients with acute coronary syndromes and elevated levels of natriuretic peptides: the results of the AVANT GARDE-TIMI 43 TrialBenjamin M Scirica, David A Morrow, Christoph Bode, et al.
European Journal of Heart Failure|June 8, 2021
Effect of sacubitril/valsartan vs. enalapril on changes in heart failure therapies over time: the PARADIGM-HF trialAnkeet S Bhatt, Muthiah Vaduganathan, Brian L Claggett, et al.
Circulation. Heart Failure|February 18, 2020
Comparison of BNP and NT-proBNP in Patients With Heart Failure and Reduced Ejection FractionRasmus Rørth, Pardeep S Jhund, Mehmet B Yilmaz, et al.
European Journal of Heart Failure|November 14, 2008
Successful treatment of heart failure with devices requires collaborationKarl Swedberg, John Cleland, Martin R Cowie, et al.
The New England Journal of Medicine|March 12, 2013
Treatment of anemia with darbepoetin alfa in systolic heart failureKarl Swedberg, James B Young, Inder S Anand, et al.
European Journal of Heart Failure|September 13, 2012
Influence of documented history of coronary artery disease on outcomes in patients admitted for worsening heart failure with reduced ejection fraction in the EVEREST trialRobert J Mentz, Bradley D Allen, Mary J Kwasny, et al.
European Heart Journal|August 31, 2015
2015 ESC Guidelines for the diagnosis and management of pericardial diseases: The Task Force for the Diagnosis and Management of Pericardial Diseases of the European Society of Cardiology (ESC)Endorsed by: The European Association for Cardio-Thoracic Surgery (EACTS)Yehuda Adler, Philippe Charron, Massimo Imazio, et al.
Pageof 48

Showing results (371-380 of 471) with videos related to

Sort By:
Pageof 48
JACC. Heart Failure|July 5, 2023
Prevalent and Incident Anemia in PARADIGM-HF and the Effect of Sacubitril/ValsartanJames P Curtain, Carly Adamson, Kieran F Docherty, et al.
American Heart Journal|July 6, 2010
Fatal myocardial rupture after acute myocardial infarction complicated by heart failure, left ventricular dysfunction, or both: the VALsartan In Acute myocardial iNfarcTion Trial (VALIANT)Faisal Shamshad, Satish Kenchaiah, Peter V Finn, et al.
Circulation. Heart Failure|October 12, 2017
Prognostic Value of N-Terminal Pro-B-Type Natriuretic Peptide Levels in Heart Failure Patients With and Without Atrial FibrillationSøren Lund Kristensen, Pardeep S Jhund, Ulrik M Mogensen, et al.
European Heart Journal|June 19, 2010
Patients with acute coronary syndromes and elevated levels of natriuretic peptides: the results of the AVANT GARDE-TIMI 43 TrialBenjamin M Scirica, David A Morrow, Christoph Bode, et al.
European Journal of Heart Failure|June 8, 2021
Effect of sacubitril/valsartan vs. enalapril on changes in heart failure therapies over time: the PARADIGM-HF trialAnkeet S Bhatt, Muthiah Vaduganathan, Brian L Claggett, et al.
Circulation. Heart Failure|February 18, 2020
Comparison of BNP and NT-proBNP in Patients With Heart Failure and Reduced Ejection FractionRasmus Rørth, Pardeep S Jhund, Mehmet B Yilmaz, et al.
European Journal of Heart Failure|November 14, 2008
Successful treatment of heart failure with devices requires collaborationKarl Swedberg, John Cleland, Martin R Cowie, et al.
The New England Journal of Medicine|March 12, 2013
Treatment of anemia with darbepoetin alfa in systolic heart failureKarl Swedberg, James B Young, Inder S Anand, et al.
European Journal of Heart Failure|September 13, 2012
Influence of documented history of coronary artery disease on outcomes in patients admitted for worsening heart failure with reduced ejection fraction in the EVEREST trialRobert J Mentz, Bradley D Allen, Mary J Kwasny, et al.
European Heart Journal|August 31, 2015
2015 ESC Guidelines for the diagnosis and management of pericardial diseases: The Task Force for the Diagnosis and Management of Pericardial Diseases of the European Society of Cardiology (ESC)Endorsed by: The European Association for Cardio-Thoracic Surgery (EACTS)Yehuda Adler, Philippe Charron, Massimo Imazio, et al.
Pageof 48